Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYL1001 in Moderate to Severe Dry Eye Disease
2016-003903-79Phase 3Completed
- Sponsor
- Sylentis
- Start
- Jan 2017
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tivanisiran in dry eye syndrome (DED), sponsored by Sylentis. Started Jan 2017; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2016-003903-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003903-79.